This market is closed
Trading has closed on this market while it waits to be settled. Here is what you can trade right now.
This market resolves to Yes if publicly verifiable reports or official announcements confirm that the da Vinci 5 robotic surgical system has been deployed in at least 500 additional hospitals worldwide by December 31, 2027. The count will include hospitals that adopt the system for the first time or upgrade from older models to the da Vinci 5. Deployment must be substantiated by Intuitive Surgical (the manufacturer), validated press releases, or other credible sources by the resolution date.
This market resolves to Yes if any U.S. hospital performs a fully remote (surgeon operating from a physically separate location) robotic surgery using the da Vinci 5 system by January 31, 2027. Verification will depend on public announcements, press releases, or trusted reporting from reputable medical or news organizations.
This market resolves to Yes if the FDA officially approves any AI-based tool for translating clinical trial consent forms by March 31, 2027. Approval must be publicly announced by the FDA or the tool's developers, and explicitly described as intended for use in translating clinical trial consent forms.
This market resolves to Yes if peer-reviewed study results published by March 2027 show that the dual-drug strategy significantly improves clinical outcomes (such as progression-free survival or overall response rate) for patients with triple-negative breast cancer compared to current standard treatments.
Will the acquisition of Personalis by Tempus AI be finalized by October 15, 2026?
About this market
This market resolves to Yes if Tempus AI successfully finalizes its $1.7 billion acquisition of cancer-tech firm Personalis by October 15, 2026. Successful finalization requires an official announcement from Tempus AI, Personalis, or relevant regulators confirming the deal's closure. If the acquisition is announced as abandoned or not completed by the resolution date, this market will resolve to No.
Rules
- Market closes at 10/15/2026.
- Logic weighted resolution applies.
The market seems to be underestimating the odds of this acquisition going through. Personalis had a strong Q3 and Tempus AI's track record of successful integrations suggests they are motivated to finalize it. Historical data shows that similar acquisitions in the healthcare tech space often close around 70-80% of the time within set timelines. If I were to rate this, I'd say there’s at least a 75% chance it happens by October 15. However, the bear case is that regulatory hurdles could delay the process. Still, at current prices, it feels like a solid buy.
Rationale:The comment provides a well-reasoned analysis of the acquisition's likelihood, supported by references to Personalis's recent performance and Tempus AI's history. The mention of regulatory hurdles adds a balanced perspective, though the claim about historical acquisition success rates is somewhat generalized. The weights prioritize fact-checking due to the reliance on specific data and logical reasoning, while emotional appeal is less prominent.
I think the 65% probability that this deal gets finalized by October 15 is way too optimistic. There have been some regulatory hurdles recently that might delay things. Tempus AI has a lot to gain, but Personalis may not be in a rush to complete this. I’d argue it’s more like 50/50 right now, considering the current climate in health tech.
Rationale:The comment provides a reasoned perspective on the probability of the acquisition being finalized, referencing regulatory hurdles and the interests of both companies. The factual accuracy is mostly solid, though it lacks specific evidence for the claims about regulatory hurdles. The comment is relevant to the market question and maintains a good balance between logical reasoning and emotional appeal. The weights reflect the importance of factual accuracy and logical coherence in this context.
I think the finalization of Personalis' acquisition by Tempus AI will take longer than expected; there are always regulatory hurdles in deals like this, and I wouldn't be surprised if it gets pushed back. The current price feels overly optimistic.
Rationale:The comment accurately reflects the common challenges in acquisitions, particularly regulatory hurdles, which is a valid concern. It is relevant to the market question as it discusses the potential delay in finalization. The reasoning is sound with no major logical fallacies, but the comment could benefit from more specific evidence or examples to strengthen the factual basis. The weights reflect a balanced focus on relevance and logical reasoning, with a moderate emphasis on factual accuracy due to the general nature of the claims.
I think this acquisition is going to face some hurdles before it's finalized. There are regulatory challenges and both companies have to align their strategies, so I wouldn't be so sure it'll happen by October.
Rationale:The comment accurately identifies potential hurdles such as regulatory challenges and the need for strategic alignment, which are relevant to the acquisition's timeline. The reasoning is sound and free from logical fallacies, making it a well-balanced argument. The weights reflect the importance of factual accuracy and logical reasoning in assessing the likelihood of the acquisition's completion by the specified date.
The current odds seem way too optimistic. Personalis was pretty hesitant about the acquisition before. There's regulatory scrutiny in the mix as well, which usually adds a lot of time. I'd give it a lower probability based on past similar deals not going through smoothly, unless new developments come up.
Rationale:The comment provides a reasonable assessment of the situation, referencing past hesitance from Personalis and the potential impact of regulatory scrutiny, which are valid points. The scores reflect a strong logical structure with minimal fallacies, and while the comment is relevant, it could benefit from more specific data to enhance the factual accuracy. The weights prioritize fact-checking slightly lower due to the speculative nature of the comment, focusing more on logical reasoning and relevance.
I think this acquisition is likely to go through, considering the strategic fit between the two companies. However, the current price seems too high for the risks involved; I would expect some fluctuations in the coming weeks.
Rationale:The comment presents a reasonable assessment of the acquisition's likelihood based on strategic fit, which is a verifiable fact, but lacks specific evidence to support the claim about the current price being too high. It is logically sound with no fallacies detected, and it directly addresses the market question while incorporating some emotional elements regarding price concerns. The weights reflect the importance of factual accuracy and logical reasoning in this context.
That price seems way too high given the uncertainty around merger approvals lately.
Rationale:The comment accurately reflects concerns about merger approvals, which is a relevant factor in the market question. While it does not provide specific evidence for the claim about the price being too high, it is a reasonable assertion given the context. The weights reflect a balance between factual accuracy and logical reasoning, with a slight emphasis on relevance due to the direct connection to the market question.
I think this acquisition is highly likely to go through, especially given the strategic fit between the two companies; however, I believe the market is underestimating potential regulatory hurdles. The price feels a bit optimistic right now.
Rationale:The comment presents a balanced view on the acquisition, acknowledging both the likelihood of success and potential regulatory challenges, which is factually sound. The reasoning is logical and free from fallacies, though it does contain some emotional language regarding the market's optimism. The weights reflect the importance of factual accuracy and logical reasoning in assessing the acquisition's prospects.
The current pricing on this acquisition seems overly optimistic given the regulatory hurdles in the biotech sector. Tempus has a spotty record with prior acquisitions, and the likelihood of approval seems closer to 60 percent than the prevailing sentiment suggests. If history is a guide, expect delays or complications.
Rationale:The comment provides a mostly accurate assessment of the situation, referencing regulatory hurdles and historical performance, which are relevant to the market question. While it lacks specific evidence for the 60 percent likelihood claim, it is a reasonable estimate based on the context. The weights reflect a focus on factual accuracy and relevance, as the comment hinges on the implications of regulatory challenges and past performance rather than pure emotional appeal.
I'm kinda skeptical this deal will go through by the deadline; there are always so many regulatory hurdles with acquisitions like this.
Rationale:The comment expresses skepticism about the acquisition due to potential regulatory hurdles, which is a valid concern in such deals. The factual accuracy is mostly sound, as regulatory issues are common in acquisitions, but it lacks specific evidence or data to support the claim. The weights reflect a balanced consideration of factual accuracy and logical reasoning, with a slight emphasis on relevance to the market question.